Modulation of the Osteosarcoma Expression Phenotype by MicroRNAs

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2012 Nov 8

PMID 23133552

Citations 166

Authors

Heidi M Namlos

Leonardo A Meza-Zepeda

Tale Baroy

Ingrid H G Ostensen

Stine H Kresse

Marieke L Kuijjer

Massimo Serra

Horst Burger

Anne-Marie Cleton-Jansen

Ola Myklebost

Affiliations

Soon will be listed here.

Abstract

Background: Osteosarcomas are the most common primary malignant tumors of bone and show multiple and complex genomic aberrations. miRNAs are non-coding RNAs capable of regulating gene expression at the post transcriptional level, and miRNAs and their target genes may represent novel therapeutic targets or biomarkers for osteosarcoma. In order to investigate the involvement of miRNAs in osteosarcoma development, global microarray analyses of a panel of 19 human osteosarcoma cell lines was performed.

Principal Findings: We identified 177 miRNAs that were differentially expressed in osteosarcoma cell lines relative to normal bone. Among these, miR-126/miR-126*, miR-142-3p, miR-150, miR-223, miR-486-5p and members of the miR-1/miR-133a, miR-144/miR-451, miR-195/miR-497 and miR-206/miR-133b clusters were found to be downregulated in osteosarcoma cell lines. All miRNAs in the paralogous clusters miR-17-92, miR-106b-25 and miR-106a-92 were overexpressed. Furthermore, the upregulated miRNAs included miR-9/miR-9*, miR-21*, miR-31/miR-31*, miR-196a/miR-196b, miR-374a and members of the miR-29 and miR-130/301 families. The most interesting inversely correlated miRNA/mRNA pairs in osteosarcoma cell lines included miR-9/TGFBR2 and miR-29/p85α regulatory subunit of PI3K. PTEN mRNA correlated inversely with miR-92a and members of the miR-17 and miR-130/301 families. Expression profiles of selected miRNAs were confirmed in clinical samples. A set of miRNAs, miR-1, miR-18a, miR-18b, miR-19b, miR-31, miR-126, miR-142-3p, miR-133b, miR-144, miR-195, miR-223, miR-451 and miR-497 was identified with an intermediate expression level in osteosarcoma clinical samples compared to osteoblasts and bone, which may reflect the differentiation level of osteosarcoma relative to the undifferentiated osteoblast and fully differentiated normal bone.

Significance: This study provides an integrated analysis of miRNA and mRNA in osteosarcoma, and gives new insight into the complex genetic mechanisms of osteosarcoma development and progression.

Citing Articles

MiR-134-5p inhibits the malignant phenotypes of osteosarcoma via ITGB1/MMP2/PI3K/Akt pathway.

Yan L, Zhou R, Feng Y, Li R, Zhang L, Pan Y Cell Death Discov. 2024; 10(1):193.

PMID: 38664375 PMC: 11045734. DOI: 10.1038/s41420-024-01946-z.

Li J, Wang H, Wu F, Yao J, Zhu H, Zhang M Aging (Albany NY). 2024; 16(1):665-684.

PMID: 38217543 PMC: 10817411. DOI: 10.18632/aging.205411.

Signal Pathways and microRNAs in Osteosarcoma Growth and the Dual Role of Mesenchymal Stem Cells in Oncogenesis.

Todosenko N, Khlusov I, Yurova K, Khaziakhmatova O, Litvinova L Int J Mol Sci. 2023; 24(10).

PMID: 37240338 PMC: 10219319. DOI: 10.3390/ijms24108993.

Roles of miR-196a and miR-196b in Zebrafish Motor Function.

Yuan C, Xie H, Chen X, Yuan S Biomolecules. 2023; 13(3).

PMID: 36979489 PMC: 10046552. DOI: 10.3390/biom13030554.

YBX1-interacting small RNAs and can be blocked in primary bone cancer using CADD522.

Green D, Singh A, Tippett V, Tattersall L, Shah K, Siachisumo C J Bone Oncol. 2023; 39:100474.

PMID: 36936386 PMC: 10015236. DOI: 10.1016/j.jbo.2023.100474.

References

Bianchi N, Zuccato C, Finotti A, Lampronti I, Borgatti M, Gambari R . Involvement of miRNA in erythroid differentiation. Epigenomics. 2012; 4(1):51-65. DOI: 10.2217/epi.11.104. View

Xiao C, Srinivasan L, Calado D, Patterson H, Zhang B, Wang J . Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat Immunol. 2008; 9(4):405-14. PMC: 2533767. DOI: 10.1038/ni1575. View

Wang W, Peng B, Wang D, Ma X, Jiang D, Zhao J . Human tumor microRNA signatures derived from large-scale oligonucleotide microarray datasets. Int J Cancer. 2010; 129(7):1624-34. DOI: 10.1002/ijc.25818. View

Petrocca F, Visone R, Onelli M, Shah M, Nicoloso M, De Martino I . E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer. Cancer Cell. 2008; 13(3):272-86. DOI: 10.1016/j.ccr.2008.02.013. View

Volinia S, Calin G, Liu C, Ambs S, Cimmino A, Petrocca F . A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A. 2006; 103(7):2257-61. PMC: 1413718. DOI: 10.1073/pnas.0510565103. View

Posthumadeboer J, Witlox M, Kaspers G, van Royen B . Molecular alterations as target for therapy in metastatic osteosarcoma: a review of literature. Clin Exp Metastasis. 2011; 28(5):493-503. PMC: 3081058. DOI: 10.1007/s10585-011-9384-x. View

Sylvestre Y, De Guire V, Querido E, Mukhopadhyay U, Bourdeau V, Major F . An E2F/miR-20a autoregulatory feedback loop. J Biol Chem. 2006; 282(4):2135-43. DOI: 10.1074/jbc.M608939200. View

Salmena L, Carracedo A, Pandolfi P . Tenets of PTEN tumor suppression. Cell. 2008; 133(3):403-14. DOI: 10.1016/j.cell.2008.04.013. View

Sadikovic B, Yoshimoto M, Chilton-MacNeill S, Thorner P, Squire J, Zielenska M . Identification of interactive networks of gene expression associated with osteosarcoma oncogenesis by integrated molecular profiling. Hum Mol Genet. 2009; 18(11):1962-75. DOI: 10.1093/hmg/ddp117. View

10.

Maire G, Martin J, Yoshimoto M, Chilton-MacNeill S, Zielenska M, Squire J . Analysis of miRNA-gene expression-genomic profiles reveals complex mechanisms of microRNA deregulation in osteosarcoma. Cancer Genet. 2011; 204(3):138-46. DOI: 10.1016/j.cancergen.2010.12.012. View

11.

Datta J, Kutay H, Nasser M, Nuovo G, Wang B, Majumder S . Methylation mediated silencing of MicroRNA-1 gene and its role in hepatocellular carcinogenesis. Cancer Res. 2008; 68(13):5049-58. PMC: 2562630. DOI: 10.1158/0008-5472.CAN-07-6655. View

12.

Zhang H, Cai X, Wang Y, Tang H, Tong D, Ji F . microRNA-143, down-regulated in osteosarcoma, promotes apoptosis and suppresses tumorigenicity by targeting Bcl-2. Oncol Rep. 2010; 24(5):1363-9. DOI: 10.3892/or_00000994. View

13.

Lin S, Du P, Huber W, Kibbe W . Model-based variance-stabilizing transformation for Illumina microarray data. Nucleic Acids Res. 2008; 36(2):e11. PMC: 2241869. DOI: 10.1093/nar/gkm1075. View

14.

Iorio M, Ferracin M, Liu C, Veronese A, Spizzo R, Sabbioni S . MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005; 65(16):7065-70. DOI: 10.1158/0008-5472.CAN-05-1783. View

15.

Mohseny A, Machado I, Cai Y, Schaefer K, Serra M, Hogendoorn P . Functional characterization of osteosarcoma cell lines provides representative models to study the human disease. Lab Invest. 2011; 91(8):1195-205. DOI: 10.1038/labinvest.2011.72. View

16.

Mohseny A, Hogendoorn P . Concise review: mesenchymal tumors: when stem cells go mad. Stem Cells. 2011; 29(3):397-403. DOI: 10.1002/stem.596. View

17.

Friedman R, Farh K, Burge C, Bartel D . Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2008; 19(1):92-105. PMC: 2612969. DOI: 10.1101/gr.082701.108. View

18.

Thayanithy V, Sarver A, Kartha R, Li L, Angstadt A, Breen M . Perturbation of 14q32 miRNAs-cMYC gene network in osteosarcoma. Bone. 2011; 50(1):171-81. PMC: 3755949. DOI: 10.1016/j.bone.2011.10.012. View

19.

Park S, Lee J, Ha M, Nam J, Kim V . miR-29 miRNAs activate p53 by targeting p85 alpha and CDC42. Nat Struct Mol Biol. 2008; 16(1):23-9. DOI: 10.1038/nsmb.1533. View

20.

Vasilatou D, Papageorgiou S, Pappa V, Papageorgiou E, Dervenoulas J . The role of microRNAs in normal and malignant hematopoiesis. Eur J Haematol. 2009; 84(1):1-16. DOI: 10.1111/j.1600-0609.2009.01348.x. View